KRON实时信号 | 通过Getagraph.com最大化利润

Live Chart Being Loaded With Signals

Commentary (27 Apr 2024 @ 04:00):

Stats
今日成交量	442 697
平均成交量	376 179
市值	60.10M
EPS	$0 ( 2024-03-20 )
下一个收益日期	( $-0.460 ) 2024-05-08
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.510
ATR14	$0.00300 (0.29%)

Insider Trading

Date	Person	Action	Amount	type
2024-02-21	Olek Elizabeth A	Sell	7 368	Common Stock
2024-02-16	Olek Elizabeth A	Sell	0	Common Stock
2024-02-16	Olek Elizabeth A	Sell	89 120	Stock Option (Right to Buy)
2024-02-16	Olek Elizabeth A	Sell	145 795	Stock Option (Right to Buy)
2024-02-16	Olek Elizabeth A	Sell	87 500	Stock Option (Right to Buy)

INSIDER POWER
45.50
Last 97 transactions
Buy: 7 377 688 \| Sell: 1 665 671

音量相关性

長: -0.19 (neutral)

短: -0.66 (moderate negative)

Signal:(63.835) Neutral

Kronos Bio, Inc. 相关性

10 最正相关
VVOS	0.892
PASG	0.886
SRTS	0.876
SGBX	0.876
FREQ	0.863
ATHE	0.858
CNDT	0.852
FOSL	0.846
KOD	0.841
VNET	0.84

10 最负相关
TYHT	-0.846
VERX	-0.827
BLCT	-0.81
HSTM	-0.81
XOG	-0.806

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

Kronos Bio, Inc. 相关性 - 货币/商品

0.60
( weak )

0.63
( weak )

0.00
( neutral )

0.19
( neutral )

Kronos Bio, Inc. 财务报表

Annual	2023
营收:	$6.29M
毛利润:	$1.37M (21.82 %)
EPS:	$-1.950

FY	2023
营收:	$6.29M
毛利润:	$1.37M (21.82 %)
EPS:	$-1.950

FY	2022
营收:	$0
毛利润:	$-4.46M (0.00 %)
EPS:	$-2.30

FY	2021
营收:	$0.00
毛利润:	$0.00 (0.00 %)
EPS:	$-2.79

Financial Reports:

No articles found.

Kronos Bio, Inc.

Kronos Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel cancer therapeutics. The company's product engine focuses on dysregulated transcription factors and the transcriptional regulatory networks that drive oncogenic activity. Its lead product candidate is entospletinib (ENTO), is an orally administered, selective spleen tyrosine kinase inhibitor for acute myeloid leukemia patients. The company planned registrational phase 3 clinical trial of ENTO in combination with induction chemotherapy in acute myeloid leukemia patients with NPM1 mutations. It is also developing KB-0742, an orally bioavailable inhibitor of cyclin dependent kinase 9 for the treatment of MYC-amplified solid tumors, which is in phase 1/2 clinical trial. The company was incorporated in 2017 and is headquartered in San Mateo, California.